Pharmacology Quiz: Erythropoiesis Stimulating Agents
20 questions · exam conditions
0:00
Erythropoiesis Stimulating AgentsQuestion 1 of 20

A patient with metastatic non-small cell lung cancer is receiving palliative chemotherapy. The patient develops symptomatic anemia with a hemoglobin of 8.5 g/dL. Before initiating an erythropoiesis-stimulating agent (ESA), what is the most critical discussion point and consideration according to the FDA's black box warning?

The need for prophylactic anticoagulation due to the high risk of venous thromboembolism with ESA therapy.
The potential for ESAs to shorten overall survival and/or increase the risk of tumor progression or recurrence.
The requirement for weekly hemoglobin monitoring to avoid a rapid rise and associated hypertensive crisis.
The importance of ensuring adequate iron stores, as iron deficiency is the leading cause of ESA resistance.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Erythropoiesis Stimulating Agents

Practice Erythropoiesis Stimulating Agents in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Erythropoiesis Stimulating Agents, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A patient with metastatic non-small cell lung cancer is receiving palliative chemotherapy. The patient develops symptomatic anemia with a hemoglobin of 8.5 g/dL. Before initiating an erythropoiesis-stimulating agent (ESA), what is the most critical discussion point and consideration according to the FDA's black box warning?

  1. The need for prophylactic anticoagulation due to the high risk of venous thromboembolism with ESA therapy.
  2. The potential for ESAs to shorten overall survival and/or increase the risk of tumor progression or recurrence. (correct answer)
  3. The requirement for weekly hemoglobin monitoring to avoid a rapid rise and associated hypertensive crisis.
  4. The importance of ensuring adequate iron stores, as iron deficiency is the leading cause of ESA resistance.
Explanation: The most critical consideration, as highlighted by the FDA's black box warning and the associated Risk Evaluation and Mitigation Strategy (REMS), is the potential for ESAs to decrease overall survival and increase the risk of tumor progression in cancer patients. This risk must be discussed with the patient as part of the informed consent process. ESAs should only be used for anemia due to myelosuppressive chemotherapy and are not indicated when the anticipated outcome of chemotherapy is cure.

Question 2

Several large clinical trials have raised concerns that erythropoiesis-stimulating agents may shorten survival and promote tumor progression in certain cancer patients. The proposed biological mechanism for this risk is based on the finding that:

  1. ESAs cause a profound immunosuppression by shifting hematopoietic precursors away from lymphoid lineages.
  2. ESAs induce the release of pro-angiogenic factors, such as VEGF, from erythroid precursors.
  3. increased blood viscosity impairs the delivery of chemotherapy agents to the tumor microenvironment.
  4. many non-myeloid tumor cells express functional erythropoietin receptors (EPOR) on their surface. (correct answer)
Explanation: When evaluating cancer-related risks of erythropoiesis-stimulating agents (ESAs), you need to understand that these drugs don't just affect red blood cell production—they can directly stimulate cancer cells themselves. The correct answer is D because many tumor cells express functional erythropoietin receptors (EPOR) on their surface. When ESAs like epoetin alfa or darbepoetin alfa bind to these receptors on cancer cells, they can promote cell survival, proliferation, and resistance to apoptosis. This direct stimulation of tumor cells through their own EPORs explains why ESAs may accelerate tumor progression and worsen survival outcomes in cancer patients. Option A is incorrect because ESAs don't cause profound immunosuppression by shifting precursors away from lymphoid lineages. ESAs specifically target erythroid precursors and don't significantly alter immune cell development. Option B misrepresents the mechanism—while angiogenesis is important in cancer, ESAs don't primarily work by inducing VEGF release from erythroid precursors. The concern is direct tumor stimulation, not indirect angiogenic effects. Option C suggests increased blood viscosity impairs chemotherapy delivery, but this isn't the primary proposed mechanism for tumor progression risk, and modest increases in hematocrit don't significantly affect drug delivery. Remember that when drugs target receptors found on normal cells, always consider whether those same receptors might be present on cancer cells. This "off-target" effect on tumor cells expressing the same receptors is a key mechanism underlying several cancer-related drug risks.

Question 3

A patient develops a deep vein thrombosis (DVT) while being treated with an ESA for anemia of chronic kidney disease. The patient's hemoglobin had risen from 8.5 g/dL to 11.8 g/dL over the preceding 6 weeks. Which of the following ESA-related effects is the most likely primary contributor to this thrombotic event?

  1. An increase in whole blood viscosity and potential for endothelial dysfunction. (correct answer)
  2. An increase in platelet count and reactivity that accompanies erythropoiesis.
  3. A direct activation of the coagulation cascade by the recombinant erythropoietin molecule.
  4. A decrease in the synthesis of natural anticoagulants, such as Protein C and Protein S.
Explanation: When you encounter ESA-related thrombotic complications, focus on the primary mechanism: increased red blood cell mass and its consequences for blood flow dynamics. ESAs (erythropoiesis-stimulating agents) like epoetin alfa work by stimulating red blood cell production, which is exactly what happened here—the patient's hemoglobin rose significantly from 8.5 to 11.8 g/dL. This substantial increase in red blood cell mass directly increases whole blood viscosity, making blood thicker and more resistant to flow. Higher viscosity creates increased shear stress on blood vessel walls, potentially damaging the endothelium and creating a prothrombotic environment. This mechanical effect is the primary driver of ESA-associated thrombotic risk, which is why target hemoglobin levels are carefully monitored during ESA therapy. Looking at the incorrect options: Option B is wrong because ESAs don't significantly increase platelet count or reactivity—their primary target is the erythroid lineage, not megakaryocytes. Option C is incorrect because recombinant erythropoietin doesn't directly activate coagulation factors; the thrombotic risk is secondary to increased red cell mass. Option D is wrong because ESAs don't decrease natural anticoagulant synthesis—Protein C and Protein S levels aren't directly affected by erythropoietin. Study tip: Remember that ESA thrombotic risk is dose-dependent and related to how quickly hemoglobin rises. When you see ESA complications, think "viscosity first"—the mechanical effects of increased red blood cell mass are the primary concern, not direct effects on platelets or coagulation factors.

Question 4

A 68-year-old male with stage 4 chronic kidney disease (CKD) and anemia is managed with darbepoetin alfa. His hemoglobin has been stable at 11.5 g/dL for 3 months, and his blood pressure is 145/90 mmHg on two antihypertensives. He reports feeling well. What is the most appropriate next step in managing his anemia therapy?

  1. Increase the darbepoetin alfa dose to target a hemoglobin of 12.5 g/dL for further quality of life improvement.
  2. Discontinue darbepoetin alfa immediately due to the risk of cardiovascular events and uncontrolled hypertension.
  3. Reduce the darbepoetin alfa dose to maintain a hemoglobin level closer to 10.0-10.5 g/dL. (correct answer)
  4. Add a third antihypertensive agent to better control blood pressure while maintaining the current ESA dose.
Explanation: The correct action is to reduce the darbepoetin alfa dose. For patients with CKD, targeting a hemoglobin level greater than 11 g/dL with an Erythropoiesis-Stimulating Agent (ESA) is associated with an increased risk of serious cardiovascular events, including stroke, myocardial infarction, and death, without providing additional benefit. The current hemoglobin of 11.5 g/dL is above the recommended target range. The goal is to use the lowest ESA dose sufficient to reduce the need for red blood cell transfusions, generally maintaining a hemoglobin level between 10 and 11 g/dL.

Question 5

Methoxy polyethylene glycol-epoetin beta is a continuous erythropoietin receptor activator with a very long half-life, allowing for once-monthly administration. What is the primary molecular feature responsible for this extended duration of action?

  1. Increased sialic acid content from additional N-linked carbohydrate chains.
  2. Fusion to the Fc domain of human IgG1, similar to etanercept.
  3. Covalent integration of a large, branched polyethylene glycol (PEG) polymer. (correct answer)
  4. A modified amino acid sequence that slows its binding and dissociation from the receptor.
Explanation: Methoxy polyethylene glycol-epoetin beta is produced by covalently attaching a large, continuous PEG polymer to the epoetin beta molecule. This process, known as PEGylation, dramatically increases the molecule's size and hydrodynamic radius. This large size significantly reduces its rate of clearance, primarily by limiting renal filtration, which extends its serum half-life to approximately 130 hours, allowing for dosing intervals of 2 to 4 weeks.

Question 6

A 70-year-old male with a history of deep vein thrombosis is receiving palliative chemotherapy for prostate cancer and has a hemoglobin of 8.8 g/dL. In addition to the risk of tumor progression, which factor most contributes to the significantly increased risk of a recurrent venous thromboembolism (VTE) if an ESA is initiated?

  1. A direct pro-coagulant effect of the ESA molecule on activating Factor X.
  2. The synergistic effect of an underlying malignancy and an ESA-induced rise in blood viscosity. (correct answer)
  3. The patient's advanced age, which is the primary driver of VTE risk in this scenario.
  4. An ESA-induced thrombocytosis that occurs concurrently with the rise in red blood cells.
Explanation: The risk of VTE is multifactorial in this patient. Malignancy itself is a potent hypercoagulable state. ESA therapy adds to this risk primarily by increasing the number of red blood cells, which raises whole blood viscosity. This increased viscosity can lead to sludging of blood flow, particularly in deep veins, promoting thrombosis. This effect is synergistic with the patient's underlying cancer-associated hypercoagulability and personal history of VTE.

Question 7

A patient who has been self-administering subcutaneous epoetin alfa for several years develops sudden, transfusion-dependent anemia and a reticulocyte count near zero. A bone marrow biopsy confirms a near absence of erythroid precursors. Neutralizing anti-erythropoietin antibodies are detected. Which statement regarding this complication is most accurate?

  1. This reaction, pure red cell aplasia (PRCA), can be managed by switching to an alternative ESA like darbepoetin alfa.
  2. The patient should be immediately restarted on the same ESA via the intravenous route to bypass skin immune cells.
  3. This complication is an idiosyncratic reaction unrelated to the formation of neutralizing antibodies.
  4. All ESA therapy must be permanently discontinued, and immunosuppressive therapy may be required. (correct answer)
Explanation: When you encounter a case of pure red cell aplasia (PRCA) with neutralizing anti-erythropoietin antibodies, you're dealing with one of the most serious complications of erythropoiesis-stimulating agent (ESA) therapy. This immune-mediated reaction occurs when the body develops antibodies that neutralize both the administered ESA and the patient's endogenous erythropoietin. The correct answer is D because neutralizing antibodies cross-react with all ESAs and endogenous erythropoietin. This means continuing any ESA therapy would be ineffective and potentially harmful, as it could perpetuate the immune response. Complete discontinuation is essential, and immunosuppressive therapy (such as corticosteroids or cyclosporine) is often necessary to suppress antibody production and allow recovery of erythropoiesis. Option A is incorrect because switching to darbepoetin alfa won't help—the neutralizing antibodies recognize the common erythropoietin epitopes shared by all ESAs. Option B misunderstands the mechanism; this isn't a local skin reaction but a systemic immune response, so changing the route of administration is irrelevant. The antibodies will neutralize the drug regardless of how it's given. Option C contradicts the question stem, which explicitly states that neutralizing antibodies are present—this is precisely an antibody-mediated reaction, not an idiosyncratic one. Remember this key principle: when you see PRCA with neutralizing anti-erythropoietin antibodies, think "complete ESA cessation plus immunosuppression." This is a rare but serious complication that requires aggressive management to prevent permanent bone marrow damage.

Question 8

The use of erythropoiesis-stimulating agents (ESAs) is restricted in cancer patients to those receiving myelosuppressive chemotherapy for non-myeloid malignancies. What is the primary rationale for avoiding ESA use in patients with myeloid malignancies such as acute myeloid leukemia (AML)?

  1. Patients with myeloid malignancies are typically not anemic and do not require ESA support.
  2. The risk of developing pure red cell aplasia (PRCA) is unacceptably high in patients with myeloid malignancies.
  3. ESAs are rapidly metabolized by leukemic blasts, rendering them ineffective in this population.
  4. The malignant myeloid progenitor cells may express the erythropoietin receptor and be stimulated to proliferate. (correct answer)
Explanation: When you encounter questions about drug restrictions in specific cancer types, think about the underlying biology of the malignancy and how the drug mechanism might interact with the cancer cells themselves. ESAs like epoetin alfa and darbepoetin alfa work by binding to erythropoietin receptors, stimulating red blood cell production. The critical concern with myeloid malignancies is that the cancerous cells originate from the same bone marrow stem cells that normally differentiate into red blood cells. These malignant myeloid progenitor cells often retain erythropoietin receptors on their surface. When you administer ESAs, you risk providing a growth signal directly to the cancer cells, potentially accelerating disease progression or interfering with treatment response. This is why ESAs are restricted to patients with non-myeloid cancers (like solid tumors) who are receiving myelosuppressive chemotherapy. Option A is incorrect because myeloid malignancy patients frequently develop anemia due to bone marrow infiltration and chemotherapy effects. Option B misidentifies the primary concern - while PRCA is a known ESA complication, it's not specifically elevated in myeloid malignancies compared to other cancers. Option C incorrectly suggests a pharmacokinetic issue; ESAs aren't preferentially metabolized by leukemic blasts. Study tip: Remember that cancer treatment restrictions often relate to whether the drug might directly benefit the cancer cells. Always consider if the malignant cells could express the same receptors or pathways that the therapeutic drug targets.

Question 9

A patient on hemodialysis receiving a stable dose of epoetin alfa demonstrates a gradual decline in hemoglobin despite dose increases. Laboratory results show: Hgb 7.9 g/dL, ferritin 90 ng/mL, and transferrin saturation (TSAT) 15%. Which of the following is the most likely cause for this patient's hyporesponsiveness to ESA therapy?

  1. Development of neutralizing anti-erythropoietin antibodies causing pure red cell aplasia (PRCA).
  2. Insufficient dialysis adequacy leading to increased uremic suppression of the bone marrow.
  3. Functional iron deficiency limiting the capacity for effective erythropoiesis. (correct answer)
  4. An underlying chronic inflammatory state, such as a occult infection, inhibiting hematopoiesis.
Explanation: The most common cause of ESA hyporesponsiveness is iron deficiency. This patient exhibits functional iron deficiency, characterized by a low TSAT (<20%) indicating insufficient iron availability for incorporation into heme, despite seemingly adequate storage iron (ferritin >50 ng/mL). The bone marrow's iron requirements are markedly increased by ESA therapy, and without sufficient available iron, red blood cell production cannot keep pace, leading to resistance.

Question 10

A 68-year-old male with stage 4 chronic kidney disease (CKD) and anemia is managed with darbepoetin alfa. His hemoglobin has been stable at 11.5 g/dL for 3 months, and his blood pressure is 145/90 mmHg on two antihypertensives. He reports feeling well. What is the most appropriate next step in managing his anemia therapy?

  1. Increase the darbepoetin alfa dose to target a hemoglobin of 12.5 g/dL for further quality of life improvement.
  2. Discontinue darbepoetin alfa immediately due to the risk of cardiovascular events and uncontrolled hypertension.
  3. Reduce the darbepoetin alfa dose to maintain a hemoglobin level closer to 10.0-10.5 g/dL. (correct answer)
  4. Add a third antihypertensive agent to better control blood pressure while maintaining the current ESA dose.
Explanation: The correct action is to reduce the darbepoetin alfa dose. For patients with CKD, targeting a hemoglobin level greater than 11 g/dL with an Erythropoiesis-Stimulating Agent (ESA) is associated with an increased risk of serious cardiovascular events, including stroke, myocardial infarction, and death, without providing additional benefit. The current hemoglobin of 11.5 g/dL is above the recommended target range. The goal is to use the lowest ESA dose sufficient to reduce the need for red blood cell transfusions, generally maintaining a hemoglobin level between 10 and 11 g/dL.

Question 11

Methoxy polyethylene glycol-epoetin beta is a continuous erythropoietin receptor activator with a very long half-life, allowing for once-monthly administration. What is the primary molecular feature responsible for this extended duration of action?

  1. Increased sialic acid content from additional N-linked carbohydrate chains.
  2. Fusion to the Fc domain of human IgG1, similar to etanercept.
  3. Covalent integration of a large, branched polyethylene glycol (PEG) polymer. (correct answer)
  4. A modified amino acid sequence that slows its binding and dissociation from the receptor.
Explanation: Methoxy polyethylene glycol-epoetin beta is produced by covalently attaching a large, continuous PEG polymer to the epoetin beta molecule. This process, known as PEGylation, dramatically increases the molecule's size and hydrodynamic radius. This large size significantly reduces its rate of clearance, primarily by limiting renal filtration, which extends its serum half-life to approximately 130 hours, allowing for dosing intervals of 2 to 4 weeks.

Question 12

A patient with CKD is initiated on ESA therapy. The initial hemoglobin is 8.8 g/dL. After 4 weeks of treatment, the hemoglobin is 10.4 g/dL. Which of the following is the most appropriate assessment and action?

  1. The response is appropriate; continue the current dose and recheck hemoglobin in 4 weeks.
  2. The response is inadequate; increase the ESA dose by 25% to reach the target range more quickly.
  3. The response is too rapid; decrease the ESA dose by 25% to avoid exceeding the target range. (correct answer)
  4. The response is concerning for PRCA; discontinue the ESA immediately and obtain a reticulocyte count.
Explanation: The patient's hemoglobin has increased by 1.6 g/dL in 4 weeks (10.4 - 8.8 = 1.6). Guidelines recommend that the rate of hemoglobin rise should not exceed 1 g/dL over any 2-week period to minimize the risk of cardiovascular events and hypertension. A rise of 1.6 g/dL in 4 weeks is considered too rapid. Therefore, the most appropriate action is to reduce the ESA dose by at least 25% and monitor more frequently.

Question 13

A 62-year-old female patient with anemia of CKD is being evaluated for ESA therapy. Her medical history is significant for poorly controlled hypertension. Her blood pressure in the clinic today is 185/105 mmHg despite therapy with three agents. What is the most appropriate recommendation regarding ESA therapy?

  1. Initiate a low dose of an ESA and add a fourth antihypertensive agent concurrently.
  2. Defer initiation of ESA therapy until her blood pressure is adequately controlled. (correct answer)
  3. Administer a red blood cell transfusion and reassess the need for an ESA in one month.
  4. Initiate an ESA, as the benefits of treating anemia outweigh the risks of worsening hypertension.
Explanation: Uncontrolled hypertension is a contraindication to initiating ESA therapy. ESAs frequently cause a further increase in blood pressure, and starting treatment in a patient with already severe, uncontrolled hypertension would place them at unacceptably high risk for cardiovascular and cerebrovascular events, such as stroke or hypertensive emergency. The standard of care is to first achieve adequate blood pressure control before considering the initiation of an ESA.

Question 14

A patient with CKD-associated anemia is being switched from epoetin alfa to darbepoetin alfa. The primary molecular modification of darbepoetin alfa that accounts for its significantly longer serum half-life is:

  1. a higher binding affinity for the erythropoietin receptor, leading to more sustained intracellular signaling.
  2. the addition of two N-linked carbohydrate chains, which increases sialic acid content and reduces clearance. (correct answer)
  3. covalent attachment of a polyethylene glycol (PEG) moiety, which increases its hydrodynamic radius.
  4. its formulation in a slow-release depot preparation that provides sustained absorption from the injection site.
Explanation: Darbepoetin alfa is a hyperglycosylated analog of recombinant human erythropoietin. It contains five N-linked carbohydrate chains instead of the three found in epoetin alfa. This increased glycosylation and higher sialic acid content makes the molecule more stable in circulation and reduces its clearance rate, thereby extending its serum half-life and allowing for less frequent dosing.

Question 15

A patient with CKD is initiated on ESA therapy. The initial hemoglobin is 8.8 g/dL. After 4 weeks of treatment, the hemoglobin is 10.4 g/dL. Which of the following is the most appropriate assessment and action?

  1. The response is appropriate; continue the current dose and recheck hemoglobin in 4 weeks.
  2. The response is inadequate; increase the ESA dose by 25% to reach the target range more quickly.
  3. The response is too rapid; decrease the ESA dose by 25% to avoid exceeding the target range. (correct answer)
  4. The response is concerning for PRCA; discontinue the ESA immediately and obtain a reticulocyte count.
Explanation: The patient's hemoglobin has increased by 1.6 g/dL in 4 weeks (10.4 - 8.8 = 1.6). Guidelines recommend that the rate of hemoglobin rise should not exceed 1 g/dL over any 2-week period to minimize the risk of cardiovascular events and hypertension. A rise of 1.6 g/dL in 4 weeks is considered too rapid. Therefore, the most appropriate action is to reduce the ESA dose by at least 25% and monitor more frequently.

Question 16

A patient on hemodialysis receiving a stable dose of epoetin alfa demonstrates a gradual decline in hemoglobin despite dose increases. Laboratory results show: Hgb 7.9 g/dL, ferritin 90 ng/mL, and transferrin saturation (TSAT) 15%. Which of the following is the most likely cause for this patient's hyporesponsiveness to ESA therapy?

  1. Development of neutralizing anti-erythropoietin antibodies causing pure red cell aplasia (PRCA).
  2. Insufficient dialysis adequacy leading to increased uremic suppression of the bone marrow.
  3. Functional iron deficiency limiting the capacity for effective erythropoiesis. (correct answer)
  4. An underlying chronic inflammatory state, such as a occult infection, inhibiting hematopoiesis.
Explanation: The most common cause of ESA hyporesponsiveness is iron deficiency. This patient exhibits functional iron deficiency, characterized by a low TSAT (<20%) indicating insufficient iron availability for incorporation into heme, despite seemingly adequate storage iron (ferritin >50 ng/mL). The bone marrow's iron requirements are markedly increased by ESA therapy, and without sufficient available iron, red blood cell production cannot keep pace, leading to resistance.

Question 17

A 70-year-old male with a history of deep vein thrombosis is receiving palliative chemotherapy for prostate cancer and has a hemoglobin of 8.8 g/dL. In addition to the risk of tumor progression, which factor most contributes to the significantly increased risk of a recurrent venous thromboembolism (VTE) if an ESA is initiated?

  1. A direct pro-coagulant effect of the ESA molecule on activating Factor X.
  2. The synergistic effect of an underlying malignancy and an ESA-induced rise in blood viscosity. (correct answer)
  3. The patient's advanced age, which is the primary driver of VTE risk in this scenario.
  4. An ESA-induced thrombocytosis that occurs concurrently with the rise in red blood cells.
Explanation: The risk of VTE is multifactorial in this patient. Malignancy itself is a potent hypercoagulable state. ESA therapy adds to this risk primarily by increasing the number of red blood cells, which raises whole blood viscosity. This increased viscosity can lead to sludging of blood flow, particularly in deep veins, promoting thrombosis. This effect is synergistic with the patient's underlying cancer-associated hypercoagulability and personal history of VTE.

Question 18

Epoetin alfa is FDA-approved for use in the perioperative setting to reduce allogeneic red blood cell transfusions. In which of the following surgical populations is this strategy most clearly indicated?

  1. Anemic patients (Hgb <13 g/dL) undergoing elective, high-blood-loss orthopedic surgery. (correct answer)
  2. Non-anemic patients undergoing low-risk laparoscopic cholecystectomy.
  3. Patients undergoing emergency coronary artery bypass grafting with significant blood loss.
  4. Patients with anemia of chronic disease who are scheduled for minor dental procedures.
Explanation: When evaluating epoetin alfa use in the perioperative setting, you need to consider both the drug's mechanism and the clinical context where benefits outweigh risks. Epoetin alfa stimulates erythropoiesis, but requires 2-4 weeks to meaningfully increase hemoglobin levels, making it suitable only for elective procedures with adequate lead time. The ideal candidate for perioperative epoetin alfa has three key characteristics: baseline anemia (making transfusion more likely), elective surgery allowing preoperative treatment time, and high anticipated blood loss. Choice A perfectly matches this profile - anemic patients undergoing elective orthopedic procedures like total joint replacements, which are known for significant blood loss and allow weeks of preoperative planning. Choice B represents inappropriate use because non-anemic patients undergoing low-blood-loss procedures have minimal transfusion risk, making the expense and potential adverse effects of epoetin alfa unjustifiable. Choice C fails because emergency surgery doesn't allow the weeks needed for epoetin alfa to work - these patients need immediate intervention, not a drug that takes time to show effect. Choice D is inappropriate because minor dental procedures carry virtually no transfusion risk, regardless of baseline anemia status. Remember that epoetin alfa in the perioperative setting is about preventing transfusions in high-risk scenarios, not treating anemia in general. Look for the combination of baseline anemia + elective surgery + high blood loss risk when identifying appropriate candidates for this indication.

Question 19

Several large clinical trials have raised concerns that erythropoiesis-stimulating agents may shorten survival and promote tumor progression in certain cancer patients. The proposed biological mechanism for this risk is based on the finding that:

  1. ESAs cause a profound immunosuppression by shifting hematopoietic precursors away from lymphoid lineages.
  2. ESAs induce the release of pro-angiogenic factors, such as VEGF, from erythroid precursors.
  3. increased blood viscosity impairs the delivery of chemotherapy agents to the tumor microenvironment.
  4. many non-myeloid tumor cells express functional erythropoietin receptors (EPOR) on their surface. (correct answer)
Explanation: When evaluating cancer-related risks of erythropoiesis-stimulating agents (ESAs), you need to understand that these drugs don't just affect red blood cell production—they can directly stimulate cancer cells themselves. The correct answer is D because many tumor cells express functional erythropoietin receptors (EPOR) on their surface. When ESAs like epoetin alfa or darbepoetin alfa bind to these receptors on cancer cells, they can promote cell survival, proliferation, and resistance to apoptosis. This direct stimulation of tumor cells through their own EPORs explains why ESAs may accelerate tumor progression and worsen survival outcomes in cancer patients. Option A is incorrect because ESAs don't cause profound immunosuppression by shifting precursors away from lymphoid lineages. ESAs specifically target erythroid precursors and don't significantly alter immune cell development. Option B misrepresents the mechanism—while angiogenesis is important in cancer, ESAs don't primarily work by inducing VEGF release from erythroid precursors. The concern is direct tumor stimulation, not indirect angiogenic effects. Option C suggests increased blood viscosity impairs chemotherapy delivery, but this isn't the primary proposed mechanism for tumor progression risk, and modest increases in hematocrit don't significantly affect drug delivery. Remember that when drugs target receptors found on normal cells, always consider whether those same receptors might be present on cancer cells. This "off-target" effect on tumor cells expressing the same receptors is a key mechanism underlying several cancer-related drug risks.

Question 20

If the hemoglobin level of a patient receiving an ESA for chemotherapy-induced anemia rises to exceed 11 g/dL, what is the recommended action according to most treatment guidelines and the FDA label?

  1. Withhold the ESA dose until the hemoglobin returns to a safer range and then restart at a reduced dose. (correct answer)
  2. Increase the dose to achieve a normal hemoglobin level of 12-13 g/dL.
  3. Continue the current dose, as a higher hemoglobin may further improve quality of life.
  4. Immediately administer a unit of packed red blood cells to correct the iatrogenic polycythemia.
Explanation: When you encounter questions about ESA (erythropoiesis-stimulating agent) management, focus on the critical balance between treating anemia and avoiding cardiovascular risks from excessive hemoglobin elevation. ESAs like epoetin alfa and darbepoetin alfa carry significant safety concerns when hemoglobin levels rise too high. The FDA and major oncology guidelines establish 11 g/dL as a key threshold because higher levels increase risks of thrombotic events, cardiovascular complications, and potentially tumor progression. The standard protocol when hemoglobin exceeds 11 g/dL is to withhold the ESA until levels drop to a safer range (typically below 10 g/dL), then restart at a 25% reduced dose. This approach prevents dangerous overshooting while maintaining the therapeutic benefit. Choice A correctly describes this evidence-based safety protocol. Choice B is dangerous because pushing hemoglobin to "normal" levels (12-13 g/dL) in cancer patients receiving ESAs significantly increases mortality and cardiovascular events—this was demonstrated in multiple clinical trials that led to black box warnings. Choice C ignores established safety thresholds; quality of life improvements plateau well below 11 g/dL, while risks continue climbing. Choice D makes no sense—blood transfusions wouldn't treat ESA-induced elevated hemoglobin, and this isn't true polycythemia. Remember that ESA safety revolves around the "11 g/dL rule"—this threshold appears frequently on pharmacology exams. Always associate ESAs with their cardiovascular black box warnings and the specific hemoglobin targets that balance efficacy with safety in oncology patients.